Cytokine storm and development of autoimmune diseases as a sequel of Covid-19

Authors

DOI:

https://doi.org/10.33448/rsd-v10i11.19385

Keywords:

Covid-19; Autoimmunity; Cytokines; Immune system.

Abstract

Introduction: Researchers at Rockefeller University, New York, found in some seriously ill patients with Covid-19 a type of autoantibody that attacks other cells of the immune system. For scientists, this would be an indication that these patients had preexisting autoantibodies to the disease and that this would be the reason why they developed the severe form of Covid-19. Objective: Answer what is the evidence on the infection by Sars-CoV-2 and triggering of autoimmunity. Methodology: This is a descriptive research of the integrative literature review type, which sought to answer what is the evidence on Sars-CoV-2 infection and triggering of autoimmunity. The search was carried out through online access in the National Library of Medicine (PubMed MEDLINE), Scientific Electronic Library Online (Scielo), Cochrane Database of Systematic Reviews (CDSR), Google Scholar, Virtual Health Library (BVS) and EBSCO databases Information Services, July 2021. Results: It is believed that Covid-19 has clinical characteristics similar to autoimmune diseases, as both share major immune responses of pathogenesis. Case reports of patients who developed Guillain-Barré syndrome, autoimmune hemolytic anemia and systemic lupus erythematosus were presented. Conclusion: Sars-CoV-2 can alter self-tolerance and generate autoimmune responses through cross-reactivity with host cells. However, it will be up to the scientific community to investigate this possibility further to validate or disprove this hypothesis, given the ease of detecting autoantibodies, thus corroborating the finding that they, triggered or not by Covid-19, are really a threat of alteration in the immune system.

References

Alberti, P., Beretta, S., Piatti, M., Karantzoulis, R., Piatti, M. L., Santoro, P. & Ferrarese, C. Guillain-Barré syndrome related to COVID-19 Infection. Neurol Neuroimmunol Neuroinflamm, 7 (4), 1-5. https://doi.org/10.1212/NXI.0000000000000741

Batista, B. O., Santos, T. J. F. F. & Gonçalves, H. M. (2021). Uma análise sobre a relação da doença do coronavírus com lúpus eritematoso sistêmico. Revista Multidisciplinar, 2 (2), https://doi.org/10.51161/rems/1017

Bonometti, R., Sacchi, M. C., Stobbione, P., Lauritano, E. C., Tamiazzo, S., Marchegiani, A., Novara, E., Molinaro, E., Benedetti, I., Massone, L., Bellora, A. & Boverio, R. O primeiro caso de lúpus eritematoso sistêmico (SLE) desencadeada por infecção COVID-19. European Review for Medical and Pharmacological Sciences, 24 (1), 9695-9697.

Caress, J. B., Costoro, R. J., Simmons, Z., Scelsa, S. N., Lewis, R. A., Ahlawat, A. & Narayanaswami, P. (2020). COVID-19–associated Guillain-Barré syndrome: The Early pandemic experience. Muscle & Nerve Wiley, 62 (1), 485-491.

Chan, M., Han, S. C., Kelly, S., Tamini, M., Giglio, B. & Lewis, A. (2020). Uma série de casos de síndrome de Guillain-Barré após infecção por Covid-19 em Nova York. Neurol Clin Pract. 1-9.

Chang, S. E., Feng, A., Meng, W., Sokratis, A., Apostolidis, A., Greib, S., James, J. & Utz, P. (2021). New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19. BMJ, 1-78. https://doi.org/10.1101/2021.01.27.21250559.

Ferreira, H. H. F., Medeiros, L. G. D., Fagundes, R. B. C., Rogério, D. B., Freitas, A. E. F. D. R., Farkatt, I. G., Macedo, C. C. G., Maciel, J. F. R., Junior, F. A. A. E. S. & Villarim, C. C. (2020). Anemia hemolítica autoimune secundária à infecção por Sars-CoV-2 e suas características: revisão de literatura. Hematol Transfus Cell Ther, 42 (2), 32-33.

Gupta, A., Paliwal, V. K. & Garg, R. K. (2020). Is COVID-19-related Guillain-Barré Syndrome Different? Brain, Behavior, and Immunity, 87 (1), 177-178. https://doi.org/10.1016/j.bbi.2020.05.051

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J. & Hu Y. (2020). Características clínicas dos pacientes infectado com novo coronavírus 2019 em Wuhan, China. The Lancet. 395 (10223): 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.

Magagnoli, J., Narendran, S., Pereira, F., Crummings, T., Hardin, J. W., Pharm, S. S. S. & Ambati, J. (2020). Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. MedRxiv. Preprint, 1- 27. https://doi.org/10.1101/2020.04.16.20065920

Mao, L., Wang, M., Chen, S., He, Q., Chang, J. & Hong C. (2020). Manifestações neurológicas de pacientes hospitalizados com COVID-19 em Wuhan, China: estudo retrospectivo de série de casos. JAMA Neurol., 77 (6), 683-690.

Nesr, G., Kosky, R., Foldes, D. & Kagdi, H. (2020). Autoimmune haemolytic anaemia and a marked rise in the lymphocyte count associated with COVID-19 in a patient with treatment-na€ıve chronic lymphocytic leukaemia: a case report. British Journal of Haematology, 190 (1), 322-328.

Rana, S., Lima, A. A., Chandra, R., Valeriano, J., Desai, T., Freiberg, W. & Small, G. (2020). Novo Coronavírus (COVID-19) Associado a Síndrome de Guillain-Barre: relato de caso. J Clin Neuromusc Dis, 21 (4), 240-242.

Renganathan V., Dhanalakshmi, K. S., Nanda, A. & Gopinath, R. (2021). Severe haemolytic anaemia in COVID 19‑ A rare manifestation. Indian J Anaesth, 65 (1), 489-490.

Rumeileh, S. A., Abdelhak, A., Foschi, M., Tumani, H. & Otto, M. (2021). Espectro da síndrome de Guillain-Barré associado a COVID 19: uma revisão sistemática atualizada de 73 casos. Journal of Neurology, 268 (1), 1133-1170. https://doi.org/10.1007/s00415-020-10124-x

Sedaghat, Z. & Karimi, N. (2020). Síndrome de Guillain Barre associada à infecção por COVID-19: um relato de caso. Journal of Clinical Neuroscience, 76 (1), 233-235.

Toscano G., Palmerini F., Ravaglia S., Ruiz L., Invernizzi P., Cuzzoni MG., Franciotta D., Baldanti F., Daturi R., Postorino P., Cavallini A. (2020). Síndrome de Guillain Barré Associado ao SARS-CoV-2. New England Journal of Medicine, 382 (26), 2574-2576.

Zhou, Y., Han, T., Chen, J., Zhao, C. & Li, J. (2020). Clínica e Características Autoimunes de Graves e Críticos Casos cal de COVID-19. Clin Transl Sci, 13 (6), 1077-1086.

Downloads

Published

22/08/2021

How to Cite

FIGUEIREDO, B. Q. de; ARAÚJO, A. P. F.; SILVA, C. D.; CABRAL, D. A. C.; AMORIM, G. S.; MEDEIROS, G. A.; PRESOT, I. Q.; QUEIROZ, J. de M.; MIRANDA, L. D.; LESSA, M. P. P.; DELBONI, V. S. Cytokine storm and development of autoimmune diseases as a sequel of Covid-19. Research, Society and Development, [S. l.], v. 10, n. 11, p. e38101119385, 2021. DOI: 10.33448/rsd-v10i11.19385. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/19385. Acesso em: 25 nov. 2024.

Issue

Vol. 10 No. 11

Section

Health Sciences

License

Copyright (c) 2021 Bárbara Queiroz de Figueiredo; Ana Paula Ferreira Araújo; Carlos Daniel Silva; Diego Arthur Castro Cabral; Gardênia Silva Amorim; Gustavo Alves Medeiros; Isadora Queiroz Presot; Júlia de Mendonça Queiroz; Luana Damaceno Miranda; Maria Paula Pereira Lessa; Vinícius Slonski Delboni

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.